- CEO
- Christopher William Hand
- Full Time Employees
- 113
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- York Biotech Campus York YK United Kingdom YO41 1LZ
- IPO Date
- Dec 15, 2020
- Business
- Abingdon Health Plc Abingdon Health Plc (ABDX.L) develops, manufactures, and distributes lateral flow assay diagnostic tests, known as rapid tests or lateral flow immunoassays, for industries including healthcare, animal health, plant health, defence, pharmaceuticals, food, and environmental testing; offers contract development and manufacturing organization (CDMO) services encompassing full-service lateral flow assay development from proof-of-concept through scale-up, technical transfer, and routine large-scale manufacturing; provides strip and card production, device assembly, kitting, packaging, regulatory consultancy, commercial support, and analytical performance evaluation; supplies branded products such as Abingdon Simply Test self-tests, COVID-19 tests, nucleic acid lateral flow immunoassays (NALFIA) like PCRD and PCRD FLEX for detecting amplified nucleic acids via LAMP or RPA, and in-field plant health tests for pathogen detection. The company, founded in 2008 and headquartered at York Biotech Campus, Sand Hutton, York, England, with additional facilities in Doncaster, England, and Madison, Wisconsin, USA, serves global customers including wholesalers, retailers, distributors, biotech firms, and pharmaceutical companies; targets professional-use tests, self-tests, companion diagnostics, and point-of-care solutions across clinical, veterinary, agricultural, and biothreat detection segments. Recent developments include the August 2024 acquisition of regulatory service provider Compliance Solutions (Life Sciences), or CS Lifesciences, for up to £3.2 million to expand integrated CDMO capabilities; the December 2024 opening of Abingdon Analytical Ltd laboratory in Doncaster for performance evaluation services; the April 2025 launch of a US CDMO site in Madison, Wisconsin; strategic partnerships with Okos Diagnostics for avian flu (H5N1) lateral flow kits and SymbioTex for seaweed-based eco-friendly test housings; major CDMO contract wins such as a US$2 million sexually transmitted disease test project, a €2 million companion diagnostic with a European biotech, a US$2.5 million point-of-care test with a global pharmaceutical firm, a US$2 million multiplex lateral flow system, and a £800,000 UKRI-funded malaria diagnostic; and post-period fundraisings including £5.2 million in August 2024 and £3.2 million in October 2025 to support US expansion and working capital.